Indications & Uses
Victoza is indicated for:
Pharmacology
Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Its amino acid sequence is 97% homologous to endogenous human GLP-1(7-37), which makes up <20% of the total endogenous GLP-1 in circulation. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor in pancreatic beta cells that is coupled to adenylyl cyclase by the stimulatory G-protein, Gs. This raises intracellular cyclic AMP (cAMP), and insulin is released when glucose concentrations are elevated. The insulin secretion subsides as blood glucose falls and approaches euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner, and a delay in gastric emptying is part of how it lowers blood glucose.
GLP-1(7-37) has a half-life of 1.5 to 2 minutes, because the ubiquitous endogenous enzymes dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP) break it down. Liraglutide, unlike native GLP-1, is stable against metabolic degradation by both peptidases, and after subcutaneous administration its plasma half-life is 13 hours. This pharmacokinetic profile makes it suitable for once daily administration. It results from self-association that delays absorption, plasma protein binding, and stability against metabolic degradation by DPP-IV and NEP.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Detailed dosing reference is not available yet. Please follow your prescription and consult your pharmacist.
Side Effects
In clinical trials, the most common side effects of Liraglutide (those seen in 5% or more of patients) were nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Some patients also had reactions linked to the body's immune response to the medicine, including urticaria. These were more common in patients given Liraglutide (0.8%) than in patients given a comparator medicine (0.4%).
Cautions & Contraindications
Warnings & Precautions
Pancreatitis After the medicine came on the market, there were reports of pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Stop Liraglutide promptly if pancreatitis is suspected, and don't restart it if pancreatitis is confirmed. A Liraglutide pen must never be shared between patients, even if the needle is changed. Hypoglycemia Adult patients taking an insulin secretagogue or insulin may have a higher risk of hypoglycemia, including severe hypoglycemia. In pediatric patients 10 years of age and older, the risk of hypoglycemia was higher with Liraglutide whether or not insulin and/or metformin was being used. The dose of the insulin secretagogue or insulin may need to be reduced. Acute Kidney Injury Cases were reported after marketing, usually together with nausea, vomiting, diarrhea, or dehydration, and sometimes hemodialysis was needed. Use caution when starting VICTOZA® or increasing the dose in patients with renal impairment. Hypersensitivity Reactions Serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) were reported after marketing. If one occurs, stop Liraglutide and seek medical advice promptly. Acute Gallbladder Disease If cholelithiasis or cholecystitis is suspected, gallbladder studies are indicated. Pulmonary Aspiration During General Anesthesia or Deep Sedation This has been reported in patients receiving GLP-1 receptor agonists who were having elective surgeries or procedures. Patients should be told to inform their doctors about any planned surgeries or procedures.
Contraindications
Liraglutide should not be given to anyone who has a personal or family history of medullary thyroid carcinoma, or to anyone with Multiple Endocrine Neoplasia syndrome type 2. It should also not be given to a patient who has had a serious hypersensitivity reaction to liraglutide or to any of the excipients in Liraglutide.
Pregnancy & Breastfeeding
Liraglutide must not be used during pregnancy. Weight loss gives a pregnant woman no benefit, and the medicine may harm the baby. There are no data on liraglutide in pregnant women, so the risk of major birth defects and miscarriage is not known. If a patient wants to become pregnant, or if pregnancy occurs, liraglutide treatment should be stopped.
For breastfeeding, there are no data on whether liraglutide passes into human milk, what it does to a breastfed infant, or whether it affects milk production. It was found in the milk of lactating rats. The doctor and the mother should weigh the developmental and health benefits of breastfeeding against the mother's clinical need for liraglutide. They should also consider any possible adverse effects on the breastfed infant, whether from the medicine or from the mother's underlying condition.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Overdose
Overdoses of Liraglutide have been reported in clinical trials and in use after the medicine reached the market. The effects included severe nausea, severe vomiting and severe hypoglycemia. If an overdose happens, supportive treatment should be started, based on the patient's clinical signs and symptoms.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep liraglutide between 2°C and 8°C, and don't let it freeze. Once you have started using it, you can store it between 15°C and 30°C for 30 days. Keep it away from heat and light.
Drug Interactions
Common questions about Victoza 6 mg/ml
What is Victoza 6 mg/ml Injection?
Victoza 6 mg/ml Injection is a medicine that contains Liraglutide. It is made by Novo Nordisk Pharma (Pvt.) Ltd. It belongs to the GLP-1 receptor agonists group of medicines.
What is Victoza used for?
Victoza is used for: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus, Diabetes Mellitus.
What are the side effects of Victoza?
In clinical trials, the most common side effects of Liraglutide (those seen in 5% or more of patients) were nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Some patients also had reactions linked to the body's immune response to the medicine, including urticaria.
Can I take Victoza during pregnancy or while breastfeeding?
Liraglutide must not be used during pregnancy. Weight loss gives a pregnant woman no benefit, and the medicine may harm the baby. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Victoza?
Overdoses of Liraglutide have been reported in clinical trials and in use after the medicine reached the market. The effects included severe nausea, severe vomiting and severe hypoglycemia. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Victoza?
Keep liraglutide between 2°C and 8°C, and don't let it freeze. Once you have started using it, you can store it between 15°C and 30°C for 30 days.
Can I take other medicines with Victoza?
Some medicines can interact with Liraglutide, for example: Insulin (Human) 30/70. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Victoza?
Victoza is a prescription (Rx) medicine. Take it as your doctor advises.